Xiangbei Welman Pharmaceuticals

Xiangbei Welman Pharmaceutical Co., Ltd. is a prominent Chinese pharmaceutical company focused on the research, development, and large-scale production of anti-infective and cardiovascular medications. Established in 1995 and headquartered in Changsha, the company is a leader in the field of compound antibiotics, particularly those combining beta-lactam antibiotics with beta-lactamase inhibitors. Their flagship products include proprietary formulations of Piperacillin Sodium and Sulbactam Sodium, which are widely utilized in clinical settings across China. The company operates multiple GMP-certified manufacturing bases and maintains a dedicated drug research institute to drive innovation in drug delivery and formulation. Xiangbei Welman has historically sought to expand its market presence through the development of high-barrier generic drugs and improved new drug applications.